JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Myriad Genetics Inc

Открыт

СекторЗдравоохранение

6.12 -4.52

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

6.05

Макс.

6.27

Ключевые показатели

By Trading Economics

Доход

42M

-100K

Продажи

-15M

196M

Рентабельность продаж

-0.051

Сотрудники

2,700

EBITDA

-12M

-14M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+4.91% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-950M

367M

Предыдущая цена открытия

10.64

Предыдущая цена закрытия

6.12

Новостные настроения

By Acuity

50%

50%

162 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Myriad Genetics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 авг. 2025 г., 17:49 UTC

Главные движущие силы рынка

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 авг. 2025 г., 17:18 UTC

Главные движущие силы рынка

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 авг. 2025 г., 16:25 UTC

Отчет

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 авг. 2025 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise as Yen Weakens -- Market Talk

11 авг. 2025 г., 23:42 UTC

Обсуждения рынка

Global Energy Roundup: Market Talk

11 авг. 2025 г., 23:42 UTC

Обсуждения рынка

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 авг. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 авг. 2025 г., 23:32 UTC

Обсуждения рынка

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 авг. 2025 г., 23:02 UTC

Обсуждения рынка

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement 2Q Rev $25.8M >EXOD

11 авг. 2025 г., 20:14 UTC

Обсуждения рынка

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 авг. 2025 г., 19:12 UTC

Обсуждения рынка

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 авг. 2025 г., 18:56 UTC

Обсуждения рынка

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 авг. 2025 г., 18:31 UTC

Обсуждения рынка

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 авг. 2025 г., 17:43 UTC

Обсуждения рынка

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 авг. 2025 г., 17:28 UTC

Обсуждения рынка

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 авг. 2025 г., 17:16 UTC

Обсуждения рынка

Commodity Longs Fall to 11-Month Low -- Market Talk

11 авг. 2025 г., 16:42 UTC

Приобретения, слияния, поглощения

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 авг. 2025 г., 16:27 UTC

Приобретения, слияния, поглощения

BBVA Says Sabadell Offer Remains in Effect

11 авг. 2025 г., 16:26 UTC

Приобретения, слияния, поглощения

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 авг. 2025 г., 16:25 UTC

Приобретения, слияния, поглощения

Banco de Sabadell Announced TSB Sale on July 1

11 авг. 2025 г., 16:25 UTC

Приобретения, слияния, поглощения

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Сравнение c конкурентами

Изменение цены

Myriad Genetics Inc Прогноз

Целевая цена

By TipRanks

4.91% рост

Прогноз на 12 месяцев

Средняя 6.63 USD  4.91%

Максимум 9 USD

Минимум 4 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Myriad Genetics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

9 ratings

2

Покупка

6

Удержание

1

Продажа

Техническая оценка

By Trading Central

N/A / 7.55Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Weak Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

162 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.